10.00
price down icon1.38%   -0.14
after-market Handel nachbörslich: 56.50 46.50 +465.00%
loading
Schlusskurs vom Vortag:
$10.14
Offen:
$10.69
24-Stunden-Volumen:
954.68K
Relative Volume:
2.92
Marktkapitalisierung:
$634.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-159.39M
KGV:
-2.8248
EPS:
-3.5401
Netto-Cashflow:
$-105.22M
1W Leistung:
+12.99%
1M Leistung:
+67.50%
6M Leistung:
+60.51%
1J Leistung:
-17.49%
1-Tages-Spanne:
Value
$9.955
$10.73
1-Wochen-Bereich:
Value
$9.25
$10.73
52-Wochen-Spanne:
Value
$4.77
$13.17

Abivax Adr Stock (ABVX) Company Profile

Name
Firmenname
Abivax Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
69
Name
Twitter
Name
Nächster Verdiensttermin
2025-06-02
Name
Neueste SEC-Einreichungen
Name
ABVX's Discussions on Twitter

Vergleichen Sie ABVX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ABVX
Abivax Adr
10.00 561.73M 0 -159.39M -105.22M -3.5401
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Abivax Adr Stock (ABVX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-20 Eingeleitet Morgan Stanley Equal-Weight
2024-12-04 Eingeleitet JMP Securities Mkt Outperform
2024-07-29 Eingeleitet Laidlaw Buy
2024-05-20 Eingeleitet BTIG Research Buy
2024-04-29 Eingeleitet Guggenheim Buy
2024-04-29 Eingeleitet Piper Sandler Overweight
2023-11-14 Eingeleitet Leerink Partners Outperform
2023-11-14 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Abivax Adr Aktie (ABVX) Neueste Nachrichten

pulisher
Jul 22, 2025

Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment - TipRanks

Jul 22, 2025
pulisher
Jul 17, 2025

The ICU Stock Puzzle: Unraveling SeaStar Medical Holding Corp’s Fluctuating Performance - investchronicle.com

Jul 17, 2025
pulisher
Jul 14, 2025

Citizens JMP reiterates Market Outperform rating on Abivax stock - Investing.com India

Jul 14, 2025
pulisher
Jul 06, 2025

Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact - TipRanks

Jul 06, 2025
pulisher
Jul 04, 2025

Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment - TipRanks

Jul 04, 2025
pulisher
Jul 01, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 01, 2025
pulisher
Jun 27, 2025

Analyst Coverage Updates - The Globe and Mail

Jun 27, 2025
pulisher
Jun 12, 2025

Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Abivax Announces Results of its June 6, 2025 Annual General Meeting - GlobeNewswire Inc.

Jun 11, 2025
pulisher
Jun 10, 2025

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Galapagos (GLPG) and Tenet Healthcare (THC) - The Globe and Mail

Jun 10, 2025
pulisher
Jun 09, 2025

European ADRs Edge Up As Wisekey And ASML Lead Gains - Finimize

Jun 09, 2025
pulisher
Jun 04, 2025

Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks

Jun 04, 2025
pulisher
Jun 03, 2025

Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks

Jun 03, 2025
pulisher
Jun 02, 2025

Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks

Jun 02, 2025
pulisher
May 14, 2025

Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks

May 14, 2025
pulisher
Apr 29, 2025

Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks

Apr 29, 2025
pulisher
Apr 22, 2025

Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks

Apr 22, 2025
pulisher
Apr 18, 2025

Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister

Apr 18, 2025
pulisher
Apr 08, 2025

Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks

Apr 08, 2025
pulisher
Mar 27, 2025

Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 25, 2025

Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks

Mar 24, 2025
pulisher
Mar 18, 2025

Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks

Mar 17, 2025
pulisher
Mar 01, 2025

Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN

Mar 01, 2025
pulisher
Feb 24, 2025

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq

Feb 24, 2025
pulisher
Feb 11, 2025

Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance

Feb 11, 2025
pulisher
Feb 10, 2025

Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily

Feb 10, 2025
pulisher
Feb 07, 2025

Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Paylocity Holding Corp’s (PCTY) Stock: A Long-Term Performance Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Perrigo Company plc (PRGO) Stock: A Closer Look at the Moving Averages - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Analyzing the Price-to-Earnings Ratio of ICL Group Ltd (ICL) - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Tectonic Therapeutic Inc (TECX) Stock: A Review of the Recent Movement - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Healthcare Triangle Inc (HCTI) Stock: A Closer Look at the Market Potential - The News Heater

Feb 07, 2025
pulisher
Jan 30, 2025

Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks - MSN

Jan 30, 2025
pulisher
Oct 26, 2023

Citi Appointed as Depositary Bank for Abivax SA’s ADR Program - Business Wire

Oct 26, 2023

Finanzdaten der Abivax Adr-Aktie (ABVX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):